Kimberly-Clark agreed to acquire Kenvue in a cash-and-stock deal valuing the Johnson & Johnson spin-off at about $48.7 billion in enterprise value. Kenvue holders are set to receive $3.50 in cash plus 0.14625 Kimberly-Clark shares per Kenvue share, equal to $21.01 per share based on October 31 pricing, a 46% premium to Kenvue’s prior close.… The post Kimberly-Clark’s $48.7B Kenvue bet is to pay a premium amid Tylenol noise appeared first on Drug Discovery and Development.| Drug Discovery and Development
As conservatives consider how best to revitalize and depoliticize civil society in America approaching its semiquincentennial celebration, still-relevant thoughts on philanthropy and the nonprofit sector from 2009.| the Giving Review
Researchers from Nanyang Technological University Singapore discovered a new way to measure biomarkers and aid patients.| TechAcute
